AIMS/HYPOTHESIS: We aimed to examine the promoter of SUR1 for genetic variation and to determine if variants were associated with Type II (non-insulin-dependent) diabetes mellitus or measures of beta-cell function. METHODS: We examined 465 bp upstream of the ATG site in 46 Type II diabetic patients and 15 glucose tolerant control subjects by SSCP-heteroduplex analysis. RESULTS: We identified an a --> t substitution 437 bp upstream of the ATG site. The allelic frequency was similar in 455 unrelated Type II diabetic patients and in 203 glucose tolerant control subjects matched for age (0.036, [95 % CI 0.019-0.053] vs 0.034 [95 % CI 0.009-0.059]; p = 0.92). Among the glucose tolerant subjects there were no differences between non-carriers (n = 189) and carriers (n = 14) of the variant in fasting values or 30 min values of plasma glucose and serum insulin during an oral glucose tolerance test. In a study of 233 glucose tolerant offspring of and spouses to Danish Caucasian Type II diabetic patients, non-carriers (n = 193) and carriers (n = 37) of the -437 a/t polymorphism did not differ in glucose or tolbutamide stimulated insulin response during an intravenous glucose tolerance test with intravenous tolbutamide injection [AUCs-insulin (0-8) min, 2290 +/- 1660 vs 2308 +/- 1935 pmol/l x min and AUCs-insulin(20-30 min), 3113 +/- 2033 vs. 3393 +/- 2830 pmol/l x min, respectively]. CONCLUSION/ INTERPRETATION: We have identified a novel a/t polymorphism of the SUR1 gene promoter which is not associated with Type II diabetes mellitus or measures of beta-cell function. Previous reported non-functional variants of SUR1 associated with Type II diabetes mellitus still need to be accounted for.
AIMS/HYPOTHESIS: We aimed to examine the promoter of SUR1 for genetic variation and to determine if variants were associated with Type II (non-insulin-dependent) diabetes mellitus or measures of beta-cell function. METHODS: We examined 465 bp upstream of the ATG site in 46 Type II diabeticpatients and 15 glucose tolerant control subjects by SSCP-heteroduplex analysis. RESULTS: We identified an a --> t substitution 437 bp upstream of the ATG site. The allelic frequency was similar in 455 unrelated Type II diabeticpatients and in 203 glucose tolerant control subjects matched for age (0.036, [95 % CI 0.019-0.053] vs 0.034 [95 % CI 0.009-0.059]; p = 0.92). Among the glucose tolerant subjects there were no differences between non-carriers (n = 189) and carriers (n = 14) of the variant in fasting values or 30 min values of plasma glucose and serum insulin during an oral glucose tolerance test. In a study of 233 glucose tolerant offspring of and spouses to Danish Caucasian Type II diabeticpatients, non-carriers (n = 193) and carriers (n = 37) of the -437 a/t polymorphism did not differ in glucose or tolbutamide stimulated insulin response during an intravenous glucose tolerance test with intravenous tolbutamide injection [AUCs-insulin (0-8) min, 2290 +/- 1660 vs 2308 +/- 1935 pmol/l x min and AUCs-insulin(20-30 min), 3113 +/- 2033 vs. 3393 +/- 2830 pmol/l x min, respectively]. CONCLUSION/ INTERPRETATION: We have identified a novel a/t polymorphism of the SUR1 gene promoter which is not associated with Type II diabetes mellitus or measures of beta-cell function. Previous reported non-functional variants of SUR1 associated with Type II diabetes mellitus still need to be accounted for.
Authors: C S Rose; N Grarup; N T Krarup; P Poulsen; L Wegner; T Nielsen; K Banasik; K Faerch; G Andersen; A Albrechtsen; K Borch-Johnsen; J O Clausen; T Jørgensen; A Vaag; O Pedersen; T Hansen Journal: Diabetologia Date: 2009-08-08 Impact factor: 10.122
Authors: T Gylvin; R Nolsøe; T Hansen; E M D Nielsen; R Bergholdt; A E Karlsen; N Billestrup; K Borch-Johnsen; O Pedersen; T Mandrup-Poulsen; J Nerup; F Pociot Journal: Diabetologia Date: 2004-07-13 Impact factor: 10.122
Authors: S K Hansen; A P Gjesing; S K Rasmussen; C Glümer; S A Urhammer; G Andersen; C S Rose; T Drivsholm; S K Torekov; D P Jensen; C T Ekstrøm; K Borch-Johnsen; T Jørgensen; M I McCarthy; T Hansen; O Pedersen Journal: Diabetologia Date: 2004-05-29 Impact factor: 10.122
Authors: K Yanagisawa; L Hingstrup Larsen; G Andersen; T Drivsholm; A Cederberg; R Westergren; K Borch-Johnsen; O Pedersen; S Enerbäck; T Hansen Journal: Diabetologia Date: 2003-10-07 Impact factor: 10.122
Authors: Stine B Thomsen; Anette P Gjesing; Camilla N Rathcke; Claus T Ekstrøm; Hans Eiberg; Torben Hansen; Oluf Pedersen; Henrik Vestergaard Journal: PLoS One Date: 2015-07-21 Impact factor: 3.240
Authors: Andrew R Wood; Anna Jonsson; Anne U Jackson; Nan Wang; Nienke van Leewen; Nicholette D Palmer; Sayuko Kobes; Joris Deelen; Lorena Boquete-Vilarino; Jussi Paananen; Alena Stančáková; Dorret I Boomsma; Eco J C de Geus; Elisabeth M W Eekhoff; Andreas Fritsche; Mark Kramer; Giel Nijpels; Annemarie Simonis-Bik; Timon W van Haeften; Anubha Mahajan; Michael Boehnke; Richard N Bergman; Jaakko Tuomilehto; Francis S Collins; Karen L Mohlke; Karina Banasik; Christopher J Groves; Mark I McCarthy; Ewan R Pearson; Andrea Natali; Andrea Mari; Thomas A Buchanan; Kent D Taylor; Anny H Xiang; Anette P Gjesing; Niels Grarup; Hans Eiberg; Oluf Pedersen; Yii-Derr Chen; Markku Laakso; Jill M Norris; Ulf Smith; Lynne E Wagenknecht; Leslie Baier; Donald W Bowden; Torben Hansen; Mark Walker; Richard M Watanabe; Leen M 't Hart; Robert L Hanson; Timothy M Frayling Journal: Diabetes Date: 2017-05-10 Impact factor: 9.461
Authors: Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham Journal: PLoS Biol Date: 2003-10-13 Impact factor: 8.029